Advanced Cell Technology Announces Technique to Generate Human Embryonic Stem Cells that Maintains Developmental Potential of Embryo; Approach Published in Nature
Advanced Cell Technology, Inc. (OTCBB:ACTC) today reported that company scientists have successfully generated human embryonic stem cells (hES cells) using an approach that does not harm embryos. The technique is reported in an article appearing online (ahead of print) in the journal Nature. The article describes a method for deriving stem cells from human blastomeres with a single-cell biopsy technique called Preimplantation Genetic Diagnosis (PGD). This technique is used in in vitro fertilization (IVF) clinics to assess the genetic health of preimplantation embryos. The cell lines produced using this technique appear to be identical to hES cell lines derived from later-stage embryos using techniques that destroy the embryo's developmental potential. ACT had previously reported the successful use of a similar technique in mice in Nature in October 2005.
"Until now, embryonic stem cell research has been synonymous with the destruction of human embryos," stated Robert Lanza, M.D., Vice President of Research & Scientific Development at ACT, and the study's senior author. "We have demonstrated, for the first time, that human embryonic stem cells can be generated without interfering with the embryo's potential for life. Overnight culture of a single cell obtained through biopsy allows both PGD and the development of stem-cell lines without affecting the subsequent chances of having a child. To date, over 1,500 healthy children have been born following the use of PGD."
Current technology derives hES cells from the inner cell mass of later-stage embryos known as blastocysts, destroying their potential for further development. ACT's approach generates human embryonic stem cells from a single cell obtained from an 8-cell-stage embryo.
To create hES cell lines, the researchers used single cells obtained from unused embryos produced by IVF for clinical purposes. Nineteen stem-cell outgrowths and two stable hES cell lines were obtained. These cell lines were genetically normal and retained their potential to form all of the cells in the human body, including nerve, liver, blood, vascular, and retinal cells, that could potentially be used to treat a range of human diseases.
"One of the major ethical objections of those who oppose the generation of human embryonic stems cells is that all techniques, until now, have resulted in the destruction of the embryo," stated Ronald Green, Ph.D., Director of Dartmouth College's Ethics Institute and Chairman of ACT's Ethics Advisory Board. "This technique overcomes this hurdle and has the potential to play a critical role in the advancement of regenerative medicine. It also appears to be a way out of the current political impasse in this country and elsewhere."
"Our policy will be to work together with the scientific community to make new lines widely available for research," stated William M. Caldwell IV, CEO of ACT. "Our ability to create human embryonic cell lines and therapies without harming the embryo should assuage the ethical concerns of many Americans. We look forward to potentially working with partners to produce significant medical benefit through the use of this technique."
"While the continual advancement of science may, from time to time, appear to influence the political debate over human embryonic stem cell research, there are a host of good reasons to continue to allow and fund responsible and well-regulated embryo research, which may speed therapies to the bedside and improve reproductive medicine," said Michael D. West, Ph.D., President and Chief Scientific Officer of ACT.
Other ACT scientists who contributed to this paper include Drs. Irina Klimanskaya and Young Chung (co-equal first authors), Sandy Becker, and Dr. Shi-Jiang Lu.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California, and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30,, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Media: Financial Dynamics Robert Stanislaro, 212-850-5657 or Investors: The Investor Relations Group James Carbonara, 212-825-3210
Source: Business Wire (August 23, 2006 - 1:01 PM EDT)
-------------------- The difference between genius and stupidity is that genius has its limits Posts: 10204 | From: NYC | Registered: Mar 2006
| IP: Logged |
quote:Originally posted by Repoman75: Juice, how did you get in at .42??
Huge blocks going through now.
Put in the order right brfore i posted the news on the PR thread and got filled right after
-------------------- The difference between genius and stupidity is that genius has its limits Posts: 10204 | From: NYC | Registered: Mar 2006
| IP: Logged |
posted
Have streaming but caught this one on one of the IHUB boards I think it was Penny Heaven.
-------------------- The difference between genius and stupidity is that genius has its limits Posts: 10204 | From: NYC | Registered: Mar 2006
| IP: Logged |
posted
Missed this one but it sure is fun to watch. It broke through a dollar. Congrats everybody.
Posts: 2309 | From: Minnesota | Registered: Feb 2006
| IP: Logged |
posted
Advanced Cell Technology's technique seems pretty impressive. I wouldn't be surprised if a larger company buys them out for their technology.
Posts: 2321 | Registered: Aug 2006
| IP: Logged |
-------------------- The difference between genius and stupidity is that genius has its limits Posts: 10204 | From: NYC | Registered: Mar 2006
| IP: Logged |
posted
I think this could turn into more than just trade due to the coverage it is getting in all Newspapers today : CNN, NY Times , MSNBC, Newsweek, Yahoo and Google news, Boston globe etc etc
Posts: 1134 | Registered: Apr 2003
| IP: Logged |
Advanced Cell to Host Investor Conference Call to Discuss Breakthrough Technique to Generate Embryonic Stem Cells without Harming Embryo Wednesday August 23, 4:43 pm ET Proprietary Method May Remove Ethical and Political Obstacles to Stem Cell Research and Federal Funding
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 23, 2006--Advanced Cell Technology, Inc. (OTCBB:ACTC - News), developers of groundbreaking human embryonic stem cell technologies to create next-generation medical therapies, will hold an investor conference call on Friday, August 25, 2006, at 12 noon Eastern, to discuss its novel technique to generate human embryonic stem cell lines from embryos while fully preserving the embryo's potential for life and development.
The proprietary technique, which was recently published in the scientific journal "Nature," aims to resolve many of the ethical issues currently stunting embryonic stem cell research and may finally open the door to needed funding from the federal government.
During the conference call, William M. Caldwell IV, Chief Executive Officer of Advanced Cell Technology (ACT), and Dr. Michael D. West, Ph.D., President and Chief Scientific Officer of ACT, will discuss the company's scientific advances and business initiatives, and will address investor questions.
Among the primary ethical objections of those who oppose the generation of human embryonic stem cells is that all techniques, until now, have resulted in the destruction of the embryo. The company's newly published proprietary technique may overcome this hurdle, offering the potential to speed the progress of stem cell science from laboratory to bedside.
"We hope that this new technique will allow us to make stem cell lines widely available for researchers around the country," said Mr. Caldwell. "Our goal is to help accelerate basic research and enable the translation of that research into real cures and treatments for many of the world's most devastating diseases."
In the paper in "Nature," ACT scientists described their technique to generate human embryonic stem cells (hES cells) using a method for deriving stem cells from human blastomeres with a single-cell biopsy technique called Preimplantation Genetic Diagnosis (PGD). PGD is a widely used practice used at in vitro fertilization (IVF) clinics to assess the genetic health of preimplantation embryos. To date, more than 1,500 healthy children have been born following the procedure, and live with their families today.
Current embryonic stem cell technology is the source of a heated national controversy because it derives hES cells from the inner cell mass of later-stage embryos known as blastocysts, destroying their potential for further development. "What has made ACT's novel approach so groundbreaking is its ability to generate stem cell lines of equal scientific value from a single cell obtained from an 8-cell-stage embryo, while maintaining the embryo's potential to develop normally," said Mr. Caldwell.
Callers within the United States can access the conference call by calling (800) 230-1074, when prompted tell the operator you would like to connect to the 'Advanced Cell Technology conference call.' International callers can dial (612) 332-0228. An online audio web simulcast of the call will also be accessible at http://www.trilogy-capital.com/tcp/advanced_cell/.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Contact: Financial Dynamics Robert Stanislaro, 212-850-5657 (Media) or The Investor Relations Group James Carbonara, 212-825-3210 (Investors) or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
Posts: 2321 | Registered: Aug 2006
| IP: Logged |
posted
The issue of Embryos getting Destroyed, has been a major issue in almost every country working in Stem Cell Research. This end all Negative views about this Science. Right now this news is spreading like wild fire all over the world. I think this will get the most coverage ever for a penny stock, at least that I've seen.
"U.S. law currently bans federal funding of any research that harms human embryos. A White House spokeswoman said the new method's eligibility for funding could not yet be determined, "but it is encouraging to see scientists at least making serious efforts to move away from research that involves the destruction of embryos."
"I think this will become a standard way of producing stem cell lines," said Ronald M. Green, a Dartmouth College professor of religion who is an unpaid bioethics adviser to Advanced Cell Technology."
posted
This thread is fine by me Tex. Tomorrow into next week should be more than interesting. We're talking multiple day runs. Possible buyout, more funding and contracts. The possibilities right now are endless for these guys.
Haha, the White house was speaking on this sleeping giant today, how big is that. Well I'm out on the West coast. Gotta go get dinner ready for company tonight.
-------------------- Now We Movin On Up!! Posts: 211 | From: Los Angelos | Registered: Oct 2004
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Eek!]](eek.gif)
![[Big Grin]](biggrin.gif)
We need one of these every day
